On February 5, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved umbralisib (UKONIQ, TG Therapeutics), an oral kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
“The approval of umbralisib for the treatment of relapsed and refractory marginal zone lymphoma and follicular lymphoma offers patients a new treatment option, and new hope for improving patient outcomes,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
For more information on the FDA approval of umbralisib (UKONIQ), visit the FDA’s website. To learn more about treatment options for MZL and FL, visit the MZL and FL Learning Centers.
Update on Oral Therapies in Lymphoma and Chronic Lymphocytic Leukemia (CLL) Webinar
Wednesday, February 10, 2021 | 2:00 PM – 3:00 PM ET
Jonathon B. Cohen, MD, MS
Winship Cancer Institute of Emory University
REGISTER >
